Safety concerns for two eczema drugs.
D000818:Animals; D004485:Eczema / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D009369:Neoplasms / Q000139:chemically induced*; D016559:Tacrolimus / Q000009:adverse effects* / Q000031:analogs & derivatives*
D007166:Immunosuppressive Agents; C117268:pimecrolimus; D016559:Tacrolimus